Information  X 
Enter a valid email address

Angel Biotechnology (ABH)

  Print      Mail a friend

Friday 21 December, 2007

Angel Biotechnology

Grant awarded

Angel Biotechnology Holdings Plc
21 December 2007

                                                                21 December 2007

            Angel Biotechnology Holdings plc (Angel or the Company)

       Angel announces award of marketing grant from Scottish Enterprise

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract
manufacturer, is pleased to announce that Scottish Enterprise has agreed to work
with Angel on an Account Managed basis and has awarded the Company a grant of
£46,000 to assist with its rebranding and international market development
activities in 2008.

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc,
said:  'We are very pleased to receive this valuable support from Scottish
Enterprise for our rebranding and Marketing activities in 2008.  Angel is
rapidly gaining a reputation for versatility and reliability in the
Biotechnology market place world wide.  We have planned a comprehensive campaign
for 2008 that will see us taking our specialist cell therapy company message and
service offering to North America, Europe and the UK.  We are seeking to
consolidate our market position and rapidly expand our client base and pipeline.
We look forward to working closely with Scottish Enterprise and growing a very
positive relationship in the future.'

For further information, please call:
Angel Biotechnology Holdings plc                       Tel: +44 (0) 131 445 6077
Gordon Sherriff Chief Operating Officer                Tel: +44 (0) 7951 05701

Grant Thornton Corporate Finance                       
Philip Secrett, Colin Aaronson                         Tel: +44 (0) 20 7383 5100

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a biomanufacturing company offering process
development services and cGMP manufacturing to support biotechnology and
pharmaceutical companies worldwide.  Angel's principal activity is the
manufacture and supply of materials for use in early stage drug development and
pre-clinical studies, along with drug product and CMC documentation for Phases
I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team with wide ranging experience in biopharmaceutical
manufacture, gained in companies such as Glaxo, Serologicals Inc. and PPL

Angel was admitted to trading on AIM in November 2005.

More information at

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                     

a d v e r t i s e m e n t